Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.08
MDVN's Cash to Debt is ranked higher than
59% of the 1443 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. MDVN: 2.08 )
MDVN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 2.08

Equity to Asset 0.49
MDVN's Equity to Asset is ranked higher than
62% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MDVN: 0.49 )
MDVN' s 10-Year Equity to Asset Range
Min: 0.01   Max: 0.99
Current: 0.49

0.01
0.99
Interest Coverage 12.99
MDVN's Interest Coverage is ranked lower than
51% of the 654 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDVN: 12.99 )
MDVN' s 10-Year Interest Coverage Range
Min: 12.99   Max: 9999.99
Current: 12.99

12.99
9999.99
F-Score: 6
Z-Score: 15.42
M-Score: -0.09
WACC vs ROIC
4.20%
272.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 39.67
MDVN's Operating margin (%) is ranked higher than
98% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -95.34 vs. MDVN: 39.67 )
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27   Max: 66.67
Current: 39.67

-510.27
66.67
Net-margin (%) 38.91
MDVN's Net-margin (%) is ranked higher than
97% of the 1168 Companies
in the Global Biotechnology industry.

( Industry Median: -77.05 vs. MDVN: 38.91 )
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58   Max: 38.91
Current: 38.91

-496.58
38.91
ROE (%) 138.12
MDVN's ROE (%) is ranked higher than
100% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. MDVN: 138.12 )
MDVN' s 10-Year ROE (%) Range
Min: -862.65   Max: 105.07
Current: 138.12

-862.65
105.07
ROA (%) 49.30
MDVN's ROA (%) is ranked higher than
99% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. MDVN: 49.30 )
MDVN' s 10-Year ROA (%) Range
Min: -80.48   Max: 42.39
Current: 49.3

-80.48
42.39
ROC (Joel Greenblatt) (%) 305.51
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1411 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. MDVN: 305.51 )
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -201825   Max: 299.94
Current: 305.51

-201825
299.94
Revenue Growth (3Y)(%) 113.40
MDVN's Revenue Growth (3Y)(%) is ranked higher than
99% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. MDVN: 113.40 )
MDVN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 113.4
Current: 113.4

0
113.4
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MDVN Guru Trades in Q1 2014

John Burbank 3,173 sh (New)
Mario Gabelli 15,046 sh (New)
Steven Cohen 216,962 sh (+3049.85%)
Jim Simons Sold Out
» More
Q2 2014

MDVN Guru Trades in Q2 2014

Mario Gabelli 25,046 sh (+66.46%)
John Burbank Sold Out
» More
Q3 2014

MDVN Guru Trades in Q3 2014

Jim Simons 108,728 sh (New)
John Burbank 2,451 sh (New)
Paul Tudor Jones 11,585 sh (New)
Joel Greenblatt 13,970 sh (New)
Mario Gabelli Sold Out
» More
Q4 2014

MDVN Guru Trades in Q4 2014

Steven Cohen 24,200 sh (New)
Ken Fisher 2,532 sh (New)
Jim Simons 257,100 sh (+136.46%)
Joel Greenblatt 31,518 sh (+125.61%)
John Burbank Sold Out
Paul Tudor Jones 5,919 sh (-48.91%)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 42.70
MDVN's P/E(ttm) is ranked higher than
92% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 42.70 )
MDVN' s 10-Year P/E(ttm) Range
Min: 33.27   Max: 329.46
Current: 42.7

33.27
329.46
Forward P/E 31.25
MDVN's Forward P/E is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 31.25 )
N/A
PE(NRI) 41.60
MDVN's PE(NRI) is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 41.60 )
MDVN' s 10-Year PE(NRI) Range
Min: 33.25   Max: 325.93
Current: 41.6

33.25
325.93
P/B 22.60
MDVN's P/B is ranked lower than
59% of the 1612 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. MDVN: 22.60 )
MDVN' s 10-Year P/B Range
Min: 0.18   Max: 1848.25
Current: 22.6

0.18
1848.25
P/S 15.70
MDVN's P/S is ranked higher than
71% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 37.64 vs. MDVN: 15.70 )
MDVN' s 10-Year P/S Range
Min: 4.54   Max: 563.33
Current: 15.7

4.54
563.33
PFCF 52.20
MDVN's PFCF is ranked higher than
92% of the 1611 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 52.20 )
MDVN' s 10-Year PFCF Range
Min: 3.04   Max: 253.5
Current: 52.2

3.04
253.5
POCF 48.37
MDVN's POCF is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 48.37 )
MDVN' s 10-Year POCF Range
Min: 3.03   Max: 202.8
Current: 48.37

3.03
202.8
EV-to-EBIT 34.38
MDVN's EV-to-EBIT is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 34.38 )
MDVN' s 10-Year EV-to-EBIT Range
Min: -658.8   Max: 156.7
Current: 34.38

-658.8
156.7
Current Ratio 6.03
MDVN's Current Ratio is ranked higher than
78% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.39 vs. MDVN: 6.03 )
MDVN' s 10-Year Current Ratio Range
Min: 1.88   Max: 27.3
Current: 6.03

1.88
27.3
Quick Ratio 6.03
MDVN's Quick Ratio is ranked higher than
79% of the 1406 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MDVN: 6.03 )
MDVN' s 10-Year Quick Ratio Range
Min: 1.88   Max: 27.3
Current: 6.03

1.88
27.3
Days Sales Outstanding 94.91
MDVN's Days Sales Outstanding is ranked higher than
76% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. MDVN: 94.91 )
MDVN' s 10-Year Days Sales Outstanding Range
Min: 34.21   Max: 143.37
Current: 94.91

34.21
143.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 251.90
MDVN's Price/Net Cash is ranked higher than
66% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 107.00 vs. MDVN: 251.90 )
MDVN' s 10-Year Price/Net Cash Range
Min: 0.38   Max: 191.56
Current: 251.9

0.38
191.56
Price/Net Current Asset Value 57.20
MDVN's Price/Net Current Asset Value is ranked higher than
66% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. MDVN: 57.20 )
MDVN' s 10-Year Price/Net Current Asset Value Range
Min: 0.37   Max: 364.25
Current: 57.2

0.37
364.25
Price/Tangible Book 30.00
MDVN's Price/Tangible Book is ranked higher than
55% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. MDVN: 30.00 )
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 1152.75
Current: 30

0.3
1152.75
Price/DCF (Projected) 131.00
MDVN's Price/DCF (Projected) is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 131.00 )
MDVN' s 10-Year Price/DCF (Projected) Range
Min: 1.96   Max: 99.61
Current: 131

1.96
99.61
Price/Median PS Value 0.60
MDVN's Price/Median PS Value is ranked higher than
95% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. MDVN: 0.60 )
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 1.92
Current: 0.6

0.32
1.92
Price/Graham Number 7.10
MDVN's Price/Graham Number is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDVN: 7.10 )
MDVN' s 10-Year Price/Graham Number Range
Min: 0.6   Max: 10.14
Current: 7.1

0.6
10.14
Earnings Yield (Greenblatt) 2.90
MDVN's Earnings Yield (Greenblatt) is ranked higher than
91% of the 1398 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MDVN: 2.90 )
MDVN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 2.9
Current: 2.9

0.6
2.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany,
Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
current Apr 10 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compare Jan 22 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensit Oct 30 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 

More From Our Partners
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog Apr 6 2015 - ZACKS

More From Other Websites
Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015 Apr 23 2015
Medivation Announces First Quarter 2015 Financial Results Teleconference on May 7, 2015 Apr 23 2015
Credit Suisse: Medivation 'Headwinds Loom' Apr 20 2015
Medivation downgraded by Credit Suisse Apr 20 2015
Two Biotech Buyout Candidates Apr 14 2015
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog Apr 06 2015
Xtandi Beats Casodex, Set to Top Zytiga Apr 03 2015
Medivation's Xtandi Beats Casodex In Cancer Trial Apr 02 2015
Enzalutamide Demonstrates Statistically Significant Improvement in Progression Free Survival... Apr 02 2015
Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival... Apr 02 2015
Biotech: Why It's Not a Bubble Mar 31 2015
3 Biotech Stocks Bucking Short Interest Trends Mar 26 2015
Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog Mar 26 2015
Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream Mar 25 2015
ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE... Mar 24 2015
Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the... Mar 24 2015
Medivation and Astellas Announce New Enzalutamide Data Presented During Plenary Presentations at the... Mar 24 2015
Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the... Mar 24 2015
Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press... Mar 18 2015
New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association... Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK